bpc-157 mcas bpc 157 Canada Mast Cell Activation Syndrome -

A favorable recommendation from the FDA's Pharmacy Compounding Advisory Committee (PCAC), scheduled for review in July 2026, followed by formal rulemaking, is required before legal compounding access is restored

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value

Clinical trial activity has been registered but human safety data remains limited

Documentation depth varies more than purity claims, and that is usually where suppliers separate

Sermorelin and BPC-157 are two peptides that are often mentioned together, but they serve very different purposes